Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Digital PCR (dPCR) is able to anticipate the achievement of stable deep molecular response in adult chronic myeloid leukemia patients: results of the DEMONSTRATE study.
Bernardi S, Cavalleri A, Mutti S, Garuffo L, Farina M, Leoni A, Iurlo A, Bucelli C, Toffoletti E, Di Giusto S, Tiribelli M, Scaffidi L, Binotto G, Malagola M, Russo D, Bonifacio M. Bernardi S, et al. Among authors: bucelli c. Ann Hematol. 2024 Nov 29. doi: 10.1007/s00277-024-06100-4. Online ahead of print. Ann Hematol. 2024. PMID: 39611878
Bosutinib Treatment of Chronic Myeloid Leukemia in Lombardy.
Iurlo A, Bucelli C, Intermesoli T, Elena C, D'Adda M, Agostani E, Fiamenghi C, Maffioli M, Orofino N, Lunghi F, Gardellini A, Carraro MC, Inzoli A, Gigli F, Palazzolo R, Bertolli V, Cattaneo D, Pungolino EM, Gambacorti-Passerini C. Iurlo A, et al. Among authors: bucelli c. Acta Haematol. 2024 Sep 18:1-5. doi: 10.1159/000540572. Online ahead of print. Acta Haematol. 2024. PMID: 39293408
Choice of Frontline Tyrosine-Kinase Inhibitor and Early Events in Very Elderly Patients With Chronic Myeloid Leukemia in Chronic Phase: A "Campus CML" Study.
Bucelli C, Capodanno I, Miggiano MC, Cavazzini F, Crescenzi SL, Russo S, Carmosino I, Annunziata M, Sorà F, Bonifacio M, Luciano L, Caocci G, Loglisci G, Elena C, Lunghi F, Mullai R, Attolico I, Binotto G, Crisà E, Sportoletti P, Di Veroli A, Scortechini AR, Leporace AP, Maggi A, Crugnola M, Stagno F, Sancetta R, Murgano P, Rapezzi D, Luzi D, Vincelli DI, Galimberti S, Bocchia M, Fava C, Malato A, Abruzzese E, Saglio G, Specchia G, Breccia M, Iurlo A, Tiribelli M, Latagliata R. Bucelli C, et al. Eur J Haematol. 2025 Jan;114(1):37-44. doi: 10.1111/ejh.14299. Epub 2024 Sep 12. Eur J Haematol. 2025. PMID: 39263855 Free PMC article.
Prognostic and Predictive Models in Myelofibrosis.
Mora B, Bucelli C, Cattaneo D, Bellani V, Versino F, Barbullushi K, Fracchiolla N, Iurlo A, Passamonti F. Mora B, et al. Among authors: bucelli c. Curr Hematol Malig Rep. 2024 Oct;19(5):223-235. doi: 10.1007/s11899-024-00739-6. Epub 2024 Aug 24. Curr Hematol Malig Rep. 2024. PMID: 39179882 Free PMC article. Review.
Proteomic screening identifies PF4/Cxcl4 as a critical driver of myelofibrosis.
Capitanio D, Calledda FR, Abbonante V, Cattaneo D, Moriggi M, Niccolò B, Bucelli C, Tosi D, Gianelli U, Vannucchi AM, Iurlo A, Gelfi C, Balduini A, Malara A. Capitanio D, et al. Among authors: bucelli c. Leukemia. 2024 Sep;38(9):1971-1984. doi: 10.1038/s41375-024-02354-z. Epub 2024 Jul 18. Leukemia. 2024. PMID: 39025985
Long-term pharmacodynamic and clinical effects of twice- versus once-daily low-dose aspirin in essential thrombocythemia: The ARES trial.
Rocca B, Tosetto A, Petrucci G, Rossi E, Betti S, Soldati D, Iurlo A, Cattaneo D, Bucelli C, Dragani A, Di Ianni M, Ranalli P, Palandri F, Vianelli N, Beggiato E, Lanzarone G, Ruggeri M, Carli G, Elli EM, Renso R, Randi ML, Bertozzi I, Loscocco GG, Ricco A, Specchia G, Vannucchi AM, Rodeghiero F, De Stefano V, Patrono C; Aspirin Regimens in EsSential thrombocythemia (ARES) Investigators. Rocca B, et al. Among authors: bucelli c. Am J Hematol. 2024 Aug;99(8):1462-1474. doi: 10.1002/ajh.27418. Epub 2024 Jun 15. Am J Hematol. 2024. PMID: 38877813 Free article. Clinical Trial.
The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment Plan.
Malagola M, Iurlo A, Bucelli C, Abruzzese E, Bonifacio M, Stagno F, Binotto G, D'Adda M, Lunghi M, Crugnola M, Ferrari ML, Lunghi F, Castagnetti F, Rosti G, Lemoli RM, Sancetta R, Coppi MR, Corsetti MT, De Gobbi M, Romano A, Tiribelli M, Russo Rossi A, Russo S, Defina M, Farina M, Bernardi S, Butturini G, Pellizzeri S, Roccaro AM, Russo D. Malagola M, et al. Among authors: bucelli c. Clin Lymphoma Myeloma Leuk. 2024 May;24(5):323-331. doi: 10.1016/j.clml.2024.01.008. Epub 2024 Jan 25. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38369436 Free article. Clinical Trial.
70 results